Navigation Links
Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis
Date:6/12/2008

Paris, France June 12, 2008 -- Biogen Idec will present data on baminercept alfa (BG9924, LTR-Ig), the first dual-mechanism, lymphotoxin-; (LT-;) and LIGHT pathway inhibitor in development for the treatment of autoimmune diseases, including rheumatoid arthritis (RA), during the 2008 European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology at the Le Palais de Congrs de Paris. Three abstracts will be presented, including one podium presentation highlighting the Phase IIa preliminary safety and efficacy data as well as two poster presentations. The Phase IIa data suggest baminercept alfa is well tolerated. DAS, EULAR and other efficacy measures were improved in patients receiving baminercept alfa vs. patients receiving placebo and persisted up to eight weeks after the final baminercept alfa injection.

Podium presentation

  • "Preliminary safety and efficacy of Baminercept alfa (BG9924, LTR-Ig) in the treatment of rheumatoid arthritis" (Presentation OP-0122 Thursday, June 12, 13:30 CEST, Ternes Session Room)

Poster presentations

  • "Long-term safety assessment of Baminercept alfa (BG9924, LTR-Ig) in Cynomolgus monkeys (Poster FRI0156 Friday, June 13, 11:45 13:30 CEST)
  • "Treatment of cynomolgus monkeys with Baminercept alfa (BG9924, LTR-Ig) results in modulation of a specialized vasculature implicated in lymphocyte trafficking to areas of chronic inflammation" (Poster SAT0040 Saturday, June 14, 10:15 12:00 CEST)

"We are excited to take part in the Annual European Congress of Rheumatology and to share promising results for baminercept alfa," said Ajay Nirula, Director of Medical Research at Biogen Idec. "We are committed to developing new treatment options for those living with RA and are encouraged that results from the Phase IIa study suggest that innovative targeting of a new pathway may be effective in treating this disease."

Phase IIa D
'/>"/>

Contact: Rachi Govil
rachi.govil@offspringpr.com
212-798-9827
Offspring PR
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
2. New MedPAC Report: Abbreviated Biogenerics Pathway Urgently Needed
3. PCMA 2008 Agenda: Support E-Prescribing, Biogenerics; Oppose Bills that Increase Costs
4. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
5. New Bird Flu Vaccine Shows Promise
6. New research shows room for improvement in health news
7. Opting out revolution a myth: Study shows steep employment gains for women, mothers
8. New KLRI Reports Shows Longevity Science Moving Beyond Studying the Obvious to the Downward Spiral Paradigm in the Aging Process
9. New Treatment Shows Promise for Excessive Drinking
10. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
11. Blood Cancer Drug Shows Promise Against Lupus

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ec. 2 Care Support of America,s ... Advanced Illness Coordinated Care (AICC) , has be...ars of life as well as improve the quality of life...ncreasing mortality. These are the principal findi...of Managed Care (November 2009). ,, Based ...
(Date:12/2/2009)...orts. An avid tennis player and golfer, as well as...ame increasingly frustrated over time as his eyesi...disorder. Unable to return the tennis ball or see ...of a corneal transplant to restore his vision and ...covered an alternative treatment. He received a ga...
(Date:12/2/2009)...id has been a top name in the medical supply indus...ducts, professional staff, and a keen understandin... has established itself as a provider of ground am...t aid supplies distributor. The distinguished hist... its next phase with the redesign and launch of it...
(Date:12/2/2009)...ire-USNewswire/ -- The American Health Information... announced Alan F. Dowling, PhD, will be the next ...ation management (HIM) leader. Dr. Dowling,s exte...mia, systems management, strategic expertise, gove...leadership. He is scheduled to take office Januar...
(Date:12/2/2009)... At a recently concluded...l delegates came together to outline the future of... the necessary thrust. Organized by the Medical To...iation.com , the high-powered congregation of seni...tunities and requests for assistance in medical to...
Breaking Medicine News(10 mins):Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4Health News:Brandeis studies evaluate visionary approach to improving eyesight 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3
... the First,Circuit Court of Appeals reinstated a c...inst Philip Morris by unanimously rejecting Philip... federal law. The case challenges,the cigarette co...and its parent company, Altria Group, Inc.,violate...
...ration (Nasdaq: IRIX ) today announced that it ha...ate placement conducted with BlueLine Partners,whi...ransaction expenses,were approximately $4.9 millio...aserscope," said Barry G. Caldwell, IRIDEX Preside...
...ma patients, study finds , , WEDNESDAY, Se...eat anemia does not reduce the need for blood tran... reduce mortality in trauma patients. , The drug,...es, this trial found that we didn,t reduce blood t...
...on for Sport,and Physical Education (NASPE) and S&...elp to educate, challenge, and encourage all child... for a healthy and fit life. As,the new sponsor of...ed fitness education program which was developed,b...
...firm that obesity rates continued to climb in over...earn that there are some foods Americans need to,e...al population and 18,percent of pregnant moms are ...). More people might dive in to seafood,if they kn...
...ger Drowned in Her Own Fluids Afte... A lawsuit filed yesterday in Federal,Court in Mi...al Cruise,Lines ship, the Carnival Legend, committ...ho this year was,named as a "Super Lawyer" in the ...
Other Medicine News:Health News:First Circuit Court of Appeals Rules Against Philip Morris in 'Lights' Class Action 2Health News:IRIDEX Announces Closing of $5.0 Million Private Placement 2Health News:IRIDEX Announces Closing of $5.0 Million Private Placement 3Health News:IRIDEX Announces Closing of $5.0 Million Private Placement 4Health News:Controversial Anemia Drug Doesn't Cut Need for Transfusions 2Health News:Controversial Anemia Drug Doesn't Cut Need for Transfusions 3Health News:National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Children's Fitness 2Health News:National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Children's Fitness 3Health News:Eat Seafood, See Weight Loss: Recent Study Finds Another Reason to Eat Seafood for a Fit Lifestyle 2Health News:Medical Malpractice at Sea 2
(Date:12/2/2009)...N, Ohio, Dec. 2 Cardinal... on the company,s board of directors, effective im...executive vice president and president of global p...ted her tenure with the company at the close of it...r term at Schering-Plough, Cox served as president...
(Date:12/2/2009)... , LUND, Sweden, December 2 /PRNewswire/ -... dermatology and wound healing company "Pergamum" ...omising results from a,clinical Phase I/IIa study....eptide (AMP) treatment for atopic dermatitis. Atop...se where dry skin and the skin,s weakened barrier,...
(Date:12/2/2009)... HAIFA, Isreal, December 2 /PRNewswire-FirstCa...OB), a leading developer of advanced,cardiovascula...pany,s Board,of Directors approved a one-for-three...end, payable to Cardio Vascular Medical Device sha... due course the estimated date the stock,split wil...
Breaking Medicine Technology:Cardinal Health Names Carrie Cox to Board of Directors 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4Cardio Vascular Medical Device Announces Forward Stock Split 2Michael Unhjem Appointed to Board of Directors for Health Integrated 52088 1Michael Unhjem Appointed to Board of Directors for Health Integrated 52088 2Michael Unhjem Appointed to Board of Directors for Health Integrated 52088 3Sundia in Top 100 Fast growth Outsourcing Companies in China 13084 1Nycomed Announces FDA Filing for Daxas 28R 29 in COPD 52082 1Nycomed Announces FDA Filing for Daxas 28R 29 in COPD 52082 2Nycomed Announces FDA Filing for Daxas 28R 29 in COPD 52082 3
...vel self-expanding intracoronary prosthesis succes...th coronary artery disease, DOYLESTOWN, Pa., May ...ia recently became the first recipients of the vPr...ry prosthesis designed to limit,arterial injury th...Shield,also provides robust biocompatible support ...
...Company to Host Conference Call/Webcast at 8:30 a....ell Corporation,(Nasdaq: ACEL ) today announced t...rom its confirmatory Phase IIIb clinical trial of ...eet statistical significance for the,primary endpo...ioma (UMM).,However, a statistically significant i...
Other Medicine Technology:Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
...n HPLC system designed to provide fast and accurat...d in the comprehensive identification and quantita...d results for glycemic control., ,The A1c assa...e accuracy of boronate affinity columns. The resul...
StreamLAB Analytical Workcell
Osmetech OPTI CCA Touch
ABL800 FLEX Blood Gas Analyzer
Medicine Products: